Kerins Patrick J's Form 4 filing
PhaseBio Pharmaceuticals Inc (PHAS) · filed Oct 26, 2022
- Accession no.
- 0001209191-22-054647
- Filed
- Oct 26, 2022, 4:41 PM ET
- Trade date
- Oct 25, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $262.3K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kerins Patrick JCIK 0001235112 | 10% Owner |
| Sandell Scott DCIK 0001237289 | 10% Owner |
| Baskett ForestCIK 0001277631 | 10% Owner |
| New Enterprise Associates 13 LPCIK 0001452907 | 10% Owner |
| NEA 13 GP, LtdCIK 0001460751 | 10% Owner |
| NEA Partners 13, Limited PartnershipCIK 0001460752 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 25, 2022 | Common Stock | SSaleDisposed | −1,784,109 | $0.147F1 | −$262,264.02 | 4,857,525 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.13 to $0.1548, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.
Referenced by the price of 1 transaction in Table I.